Terumo Archives - Medical Design Sourcing

Terumo to build new manufacturing facility in Japan

Terumo announced that it plans to construct a new manufacturing facility for its Medical Care Solutions Company in Japan.

The company’s investment in the facility totals $382.9 million (¥52.2 billion). Terumo expects to complete construction in fiscal 2025. It’s located in the premises of the Kofu Factory in Yamanashi, Japan, according to a news release.

Once operations begin, the company plans to utilize the facility for its contract development and manufacturing organization (CDMO) business. It also plans to manufacture products related to peritoneal dialysis. Additionally, Terumo expects the facility to provide additional spaces to enable it to scale up production to meet future demand.

The Terumo CDMO business provides integrated support for drug-device combination products. This ranges from design to commercial manufacturing through partnerships with pharmaceutical companies. The company expanded its CDMO business globally over the past …

The biggest medical device VC deals of 2022

Enable Injections, which makes the enFuse device, raised $215 million in January 2022. [Photo courtesy of Enable Injections]

Last year was definitely a slower year for medical device VC deals than the year before.

Biofourmis was the only medical device developer in the 10 largest healthcare VC deals of 2022, according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB).

Because we love devices at Medical Design & Outsourcing, we asked SVB for a ranking of 2022’s largest medical device VC deals after Biofourmis, which raised $325 million in its 2022 series D round. (The year before that, CMR Surgical’s $600 million Series D financing round was the largest medical device VC deal of 2021.)

SVB obliged, once again drawing upon its own proprietary information and data from Pitchbook. The dealmakers include device developers with innovative methods for …

Medtech jobs: The world’s largest medical device companies are hiring

Medical device companies are trying to fill thousand of medtech jobs. [Photo by ijeab – stock.adobe.com]

The world’s largest medical device companies are still hiring for medtech jobs despite layoffs in tech and other industries.

Medtech developers — and medtech jobs — are resilient, with the industry’s COVID-19 pandemic performance only bolstering its recession-proof reputation.

That’s not to say there haven’t been job cuts in medtech, led by thousands of layoffs at Philips as it struggles with a massive recall of deadly respiratory devices. But most medical device manufacturers are still hiring, and in some cases they can’t attract enough candidates to fill every vacancy in a tight labor market.

Stryker, for example, grew to approximately 51,000 employees as of the end of 2022, increasing its headcount by nearly 11 percent last year. Boston Scientific reported nearl…

Inspira signs OEM agreement with Terumo Cardiovascular

Inspira Technologies (Nasdaq:INN) announced today that it signed an exclusive OEM agreement with Terumo Cardiovascular.

In a news release, Inspira called Terumo Cardiovascular “experts” in oxygenation systems, heart-lung machines and monitoring systems. The agreement covers the manufacture of a flow mechanism for integration into Inspira’s products. The company designed these products for use in the extracorporeal circulation of blood during oxygenation.

The agreement may extend to integration into the Inspira ART system for acute respiratory care. ART boosts oxygen saturation levels in minutes using small volumes of blood. Inspira designed it to treat patients while awake and breathing spontaneously. This reduces the need for invasive mechanical ventilation.

“This is a very important agreement for the company, and we believe that it is in line with our strategy towards developing collaborations with the largest medical device com…

Dexcom G6 CGMs win reimbursement coverage in Japan

The G6 platform. [Image from Dexcom]Terumo announced today that the Japanese medical insurance system expanded reimbursement coverage for the Dexcom G6 CGM.

Japan’s medical insurance system introduced a new category titled “C150.” It makes a wider range of people with diabetes eligible to receive reimbursement for the G6 continuous glucose monitor (CGM) in Japan.

Dexcom develops and manufactures the current-generation G6 CGM. It offers the next-generation Dexcom G7 CGM in the UK, Ireland, Germany, Austria and Hong Kong. U.S. approval could come soon, too. Terumo markets the G6 in Japan.

Get the full story at our sister site, Drug Delivery Business News.

Terumo, Glooko partner for diabetes data sharing with insulin patch pump

Left: Terumo’s Medisafe With insulin patch pump. Right: insulin patch pump data upload via Glooko’s mobile app. [Images from Terumo and Glooko]Terumo (TSE:4543) and Glooko today announced a collaboration to integrate their technologies and create new diabetes data sharing solutions.

In the new technology integration, users with diabetes will be able to transfer recorded data from the Terumo Medisafe With insulin patch pump into the Glooko management platform, allowing for the visualization of insulin dosage, food and activities in graphs.

Get the full story at our sister site, Drug Delivery Business News.

FDA clears Terumo’s next-gen plasma collection device

[Image from Terumo]Terumo (TSE: 4543) announced today that the FDA cleared its Rika next-generation automated plasma collection system.

Lakewood, Colorado-based Terumo designed the Rika system to include safety features that minimize operator errors while collecting plasma in 35 minutes or less.

According to a news release, the company developed Rika in response to the industry’s need for technological advancement and process improvements to drive efficiency while maintaining donor safety and a sufficient plasma supply. Terumo focused the technology on donor and plasma collection center employee experience, with a collection time of 35 minutes or less and a volume of 200 milliliters or less outside the donor’s body, there can be a more comfortable donation experience.

Rika has an advanced control system to enhance donor safety by monitoring the process and providing alerts and visual cues that guide the operator, while the platform makes automat…

Diabeloop, Terumo partner to bring automated insulin delivery to Europe

Diabeloop announced that it entered into an agreement with Terumo with eyes on bringing automated insulin delivery solutions to Europe.

Paris-based Diabeloop’s automated insulin delivery (AID) system automates and personalizes the treatment of insulin-dependent diabetes and contributes to reducing the mental burden associated with the metabolic disease.

Get the full story at our sister site, Drug Delivery Business News.

FDA committee to examine safety of endovascular stent grafts

AFX Endovascular AAA system [Image courtesy of Endologix]FDA’s CDRH Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet later this year to examine the safety of endovascular stent grafts made by Endologix and other companies.

Day one of the meeting will examine the benefit-risk profile of the Endologix AFX endovascular graft system regarding a potentially higher-than-expected risk of blood leakage called Type III endoleaks. Endologix has found itself having to vigorously defend itself against studies claiming a problem.

The FDA is presently advising that anyone with any Endologix AFX endovascular graft (AFX with Strata, AFX with Duraply, or AFX2) visits a doctor at least once a year to get checked for leaks.

Another Endologix product — the Ovation iX abdominal stent graft system — was the subject of a Class I recall last year including five deaths, though Endologix clarified that two of the five deaths took place follo…

Terumo to acquire Health Outcomes Sciences

Terumo (TSE: 4543) recently announced that it has signed a definitive agreement to acquire all assets of Health Outcomes Sciences.

The financial terms of the deal were not disclosed.

Phoenix-based HOS is a creator of predictive analytics and clinical decision support software. Its sePRISM content enablement platform is meant to enable healthcare organizations to deliver personalized, predictive, point-of-care insights.

“The acquisition of Health Outcomes Sciences and the ePrism platform expands Terumo’s presence in the digital healthcare arena and represents a compelling growth opportunity for our company,” said Toshi Osada, president of Tokyo-based Terumo’s Cardiac and Vascular Company.

“It further allows Terumo to deliver innovative digital solutions, providing healthcare systems with critical data needed to lower the cost of healthcare delivery while substantially improving patient outcomes,” Osada said in a …

FDA approves low-profile aneurysm embolization system

Terumo (TYO:4543) subsidiary MicroVention announced today that it received FDA approval of a PMA supplement for its WEB 17 system.

Aliso Viejo, Calif.-based MicroVention’s WEB 17 system is a new addition to its WEB aneurysm embolization system for treating intracranial wide-neck bifurcation aneurysms, according to a news release.

WEB 17 features a lower profile delivery system compatible with the VIA 17 microcatheter, along with additional device configurations.

When placed in the aneurysm sac, the WEB device’s proprietary microbraid technology is designed to bridge teh aneurysm neck, disrupting blood flow and creating a scaffold for long-lasting treatment. It secured its first pre-market approval in late 2018.

“The WEB 17 System has been used to enhance care for thousands of patients globally since its initial launch in 2016,” MicroVention president & CEO Carsten Schroeder said in the release. “MicroVention is…

MedTech 100 roundup: Industry hits pandemic peak

After five months since medtech stocks peaked before the COVID-19 pandemic rocked the markets, the industry inched back toward that pre-pandemic high.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 88.9 points at the end of last week (July 17). That total represents just a -3.7% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.

Medtech stocks saw a 5.1% increase from the 84.39-point total at the same time a week prior (July 10), highlighting a large improvement after last week saw almost no material change in the index.

Meanwhile, the S&P 500 Index saw a 1.2% bump from July 10 to July 17, and the Dow Jones Index fared even better, posting a 2.3% increase over the same period of time. Both indexes mirrored the medtech industry’s changes as far as increases, but didn’t see as drastic a change.

Medtech’s lowest point du…